• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Tricida Inc. (Amendment)

    2/14/23 12:19:00 PM ET
    $TCDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TCDA alert in real time by email
    SC 13G/A 1 d408376dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 1)*

     

     

    Tricida, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    89610F101

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 89610F101

     

      1.    

      Names of Reporting Persons

     

      Frazier Life Sciences Public Fund, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      1,500,000 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      1,500,000 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,500,000 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.5% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the securities held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on (i) 58,028,254 shares of Common Stock outstanding on November 9, 2022 as set forth in the Issuer’s Form 10-Q as filed with the SEC on November 14, 2022 and (ii) 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022.


    CUSIP No. 89610F101

     

      1.    

      Names of Reporting Persons

     

      FHMLSP, L.P.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      1,500,000 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      1,500,000 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,500,000 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.5% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      PN

     

    (1)

    Consists of 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the securities held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on (i) 58,028,254 shares of Common Stock outstanding on November 9, 2022 as set forth in the Issuer’s Form 10-Q as filed with the SEC on November 14, 2022 and (ii) 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022.


    CUSIP No. 89610F101

     

      1.    

      Names of Reporting Persons

     

      FHMLSP, L.L.C.

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      1,500,000 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      1,500,000 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,500,000 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.5% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      OO

     

    (1)

    Consists of 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the securities held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on (i) 58,028,254 shares of Common Stock outstanding on November 9, 2022 as set forth in the Issuer’s Form 10-Q as filed with the SEC on November 14, 2022 and (ii) 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022.


    CUSIP No. 89610F101

     

      1.    

      Names of Reporting Persons

     

      James N. Topper

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      1,500,000 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      1,500,000 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,500,000 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.5% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the securities held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on (i) 58,028,254 shares of Common Stock outstanding on November 9, 2022 as set forth in the Issuer’s Form 10-Q as filed with the SEC on November 14, 2022 and (ii) 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022.


    CUSIP No. 89610F101

     

      1.    

      Names of Reporting Persons

     

      Patrick J. Heron

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      1,500,000 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      1,500,000 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,500,000 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.5% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the securities held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on (i) 58,028,254 shares of Common Stock outstanding on November 9, 2022 as set forth in the Issuer’s Form 10-Q as filed with the SEC on November 14, 2022 and (ii) 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022.


    CUSIP No. 89610F101

     

      1.    

      Names of Reporting Persons

     

      Albert Cha

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      1,500,000 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      1,500,000 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,500,000 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.5% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the securities held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on (i) 58,028,254 shares of Common Stock outstanding on November 9, 2022 as set forth in the Issuer’s Form 10-Q as filed with the SEC on November 14, 2022 and (ii) 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022.


    CUSIP No. 89610F101

     

      1.    

      Names of Reporting Persons

     

      James Brush

      2.  

      Check the Appropriate Box if a Member of a Group (see instructions)

      (a)  ☐        (b)  ☒

     

      3.  

      SEC USE ONLY

     

      4.  

      Citizenship or Place of Organization

     

      United States Citizen

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.     

      Sole Voting Power

     

      0 shares

       6.   

      Shared Voting Power

     

      1,500,000 shares (1)

       7.   

      Sole Dispositive Power

     

      0 shares

       8.   

      Shared Dispositive Power

     

      1,500,000 shares (1)

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,500,000 shares (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row 9

     

      2.5% (2)

    12.  

      Type of Reporting Person (see instructions)

     

      IN

     

    (1)

    Consists of 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022. FHMLSP, L.P. is the general partner of Frazier Life Sciences Public Fund, L.P. and FHMLSP, L.L.C. is the general partner of FHMLSP, L.P. Patrick J. Heron, James N. Topper, Albert Cha and James Brush are the members of FHMLSP, L.L.C. and therefore share voting and investment power over the securities held by Frazier Life Sciences Public Fund, L.P.

    (2)

    Based on (i) 58,028,254 shares of Common Stock outstanding on November 9, 2022 as set forth in the Issuer’s Form 10-Q as filed with the SEC on November 14, 2022 and (ii) 1,500,000 shares of Common Stock issuable to Frazier Life Sciences Public Fund, L.P. pursuant to a warrant exercisable within 60 days of December 31, 2022.


    Item 1(a).    Name of Issuer: Tricida, Inc.
    Item 1(b).    Address of Issuer’s Principal Executive Offices: 7000 Shoreline Court, Suite 201, South San Francisco, CA 94080
    Item 2(a).   

    Name of Person Filing:

     

    The entities and persons filing this statement (collectively, the “Reporting Persons”) are:

     

    Frazier Life Sciences Public Fund, L.P. (“FLSPF”)

    FHMLSP, L.P.

    FHMLSP, L.L.C.

    James N. Topper (“Topper”)

    Patrick J. Heron (“Heron”)

    Albert Cha (“Cha”)

    James Brush (“Brush” and together with Topper, Heron and Cha, the “Members”)

    Item 2(b).   

    Address of Principal Business Office or, if none, Residence:

     

    The address and principal business office of the Reporting Persons is:

     

    c/o Frazier Life Sciences Management, L.P.

    70 Willow Road, Suite 200

    Menlo Park, CA 94025

     

    Item 2(c).   Citizenship:         
      Entities:    FLSPF    -    Delaware, U.S.A.
         FHMLSP, L.P.    -    Delaware, U.S.A.
         FHMLSP, L.L.C.    -    Delaware, U.S.A.
      Individuals:    Topper    -    United States Citizen
         Heron    -    United States Citizen
         Cha    -    United States Citizen
         Brush    -    United States Citizen

     

    Item 2(d).   Title of Class of Securities: Common Stock
    Item 2(e).   CUSIP Number: 89610F101
    Item 3.   If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)           ☐    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
    (b)           ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)           ☐    Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);
    (d)           ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)           ☐    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)           ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)           ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)           ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)           ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)           ☐    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)           ☐    Group, in accordance with §240.13d–1(b)(1)(ii)(K).
      If filing as a non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J), please specify the type of institution:  ☐


    Item 4.

    Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

     

      (a)

    Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

     

      (b)

    Percent of Class: See Row 11 of cover page for each Reporting Person

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

     

      (ii)

    Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

     

      (iii)

    Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

     

      (iv)

    Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☒.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Each member of the group is identified on the signature page to this Schedule 13G amendment.

     

    Item 9.

    Notice of Dissolution of a Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2023     FRAZIER LIFE SCIENCES PUBLIC FUND, L.P.
        By: FHMLSP, L.P., its General Partner
        By: FHMLSP, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: February 14, 2023     FHMLSP, L.P.
        By: FHMLSP, L.L.C., its General Partner
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: February 14, 2023     FHMLSP, L.L.C.
        By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, Chief Financial Officer
    Date: February 14, 2023     By:  

    *

          James N. Topper
    Date: February 14, 2023     By:  

    *

          Patrick J. Heron
    Date: February 14, 2023     By:  

    **

          Albert Cha
    Date: February 14, 2023     By:  

    **

          James Brush
    Date: February 14, 2023     By:  

    /s/ Steve R. Bailey

          Steve R. Bailey, as Attorney-in-Fact

     

    *

    This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

    **

    This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021.

    Get the next $TCDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCDA

    DatePrice TargetRatingAnalyst
    4/13/2022$25.00Buy
    Goldman
    11/16/2021$7.00Underweight → Neutral
    JP Morgan
    More analyst ratings